Compare RSVR & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSVR | AQST |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.0M | 529.4M |
| IPO Year | 2020 | 2007 |
| Metric | RSVR | AQST |
|---|---|---|
| Price | $9.66 | $4.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $13.00 | $9.33 |
| AVG Volume (30 Days) | 62.3K | ★ 2.1M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.33 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $175,664,491.00 | $67,430,000.00 |
| Revenue This Year | $7.04 | $12.09 |
| Revenue Next Year | $5.58 | $35.73 |
| P/E Ratio | $73.62 | ★ N/A |
| Revenue Growth | ★ 10.69 | 0.77 |
| 52 Week Low | $7.07 | $2.94 |
| 52 Week High | $13.39 | $7.55 |
| Indicator | RSVR | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 53.29 | 47.09 |
| Support Level | $9.50 | $4.51 |
| Resistance Level | $9.69 | $4.69 |
| Average True Range (ATR) | 0.24 | 0.22 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 85.31 | 28.36 |
Reservoir Media Inc is an independent music company. The company operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the U.S. Music Publishing segment engaged in the acquisition of interests in music catalogs to earn royalties and signing songwriters to agreements of future delivery of songs. The Recorded Music segment involve the acquisition of sound recording catalogs and the discovery and development of recording artists and the marketing, distribution, sale and licensing of the music catalog.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.